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Abstract
Background: Juvenile dermatomyositis (JDM) is the most common form of the idiopathic inflammatory myopathies in
children. A subset of children have the rash of JDM without significant weakness, and the optimal treatments for these
children are unknown. The goal of this study was to describe the development of consensus clinical treatment plans
(CTPs) for children with JDM who have active skin rashes, without significant muscle involvement, referred to as skin
predominant JDM in this manuscript.
Methods: The Children’s Arthritis and Rheumatology Research Alliance (CARRA) is a North American consortium of
pediatric rheumatology health care providers. CARRA members collaborated to determine consensus on typical
treatments for JDM patients with skin findings without significant weakness, to develop CTPs for this subgroup of
patients. We used a combination of Delphi surveys and nominal group consensus meetings to develop these CTPs.
Results: Consensus was reached on patient characteristics and outcome assessment, and CTPs were developed and
finalized for patients with skin predominant JDM. Treatment option A included hydroxychloroquine alone, Treatment
option B included hydroxychloroquine and methotrexate, and Treatment option C included hydroxychloroquine,
methotrexate and corticosteroids.
Conclusions: Three CTPs were developed for use in children with skin predominant JDM, which reflect typical
treatment approaches. These are not considered to be specific recommendations or standard of care. Using
the CARRA network and prospective data collection, we will be able to apply statistical methods in the future
to allow comparisons of JDM patients following these consensus treatment plans.
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Background
Juvenile Dermatomyositis (JDM) is the most common
form of the idiopathic inflammatory myopathies in chil-
dren but is relatively rare, affecting about 1–3 per 1 million
children annually in the United States [1, 2]. It is a diffuse
vasculopathy with inflammation in skin and muscle, typic-
ally associated with weakness and physical limitations.
Classic cutaneous manifestations which are pathogno-
monic for the diagnosis of JDM include Gottron’s papules
and heliotrope rash. Malar rash and nailbed capillary
changes are also frequently present [3]. JDM patients typ-
ically have proximal muscle weakness, but a subset of pa-
tients present with skin disease without any significant
weakness or muscle inflammation [4, 5].
General designations for this subset of JDM patients
have included: amyopathic dermatomyositis (DM), clin-
ically amyopathic DM, DM sine myositis, and hypomyo-
pathic DM, among others [5–9]. These generally have
intended to describe the subset of DM patients with typ-
ical skin disease of DM but without clinically significant
weakness. For this publication, we will use the term skin
predominant JDM to describe the patient subtype under
consideration.
The epidemiology, treatment and outcomes of skin
predominant JDM are not well studied. The largest
series of clinically amyopathic JDM patients published
included 68 cases, of which about 25% progressed to
classical JDM [10]. Few patients with clinically amyo-
pathic JDM in this series developed disease-related com-
plications: only 4% developed calcinosis and no patients
developed vasculopathy, interstitial lung disease or ma-
lignancy [10].
The best treatments for JDM and skin predominant
JDM are not known, and treatments used are extremely
variable [11]. Proposed therapy of skin predominant
JDM includes recommendations for topical and systemic
therapies, without trial data or case experiences to sup-
port these approaches [12].
Presently available retrospective studies in JDM are
limited by small sample sizes, lack of blinding, and lack
of generalizability. Efforts to conduct a traditional ran-
domized controlled trial to conclusively evaluate the best
treatment of skin predominant JDM are associated with
many challenges. First, the rarity of skin predominant
JDM, which is a subset of an already uncommon condi-
tion, limits its successful study due to the inability to ac-
crue sufficient numbers of patients from a reasonable
number of sites, over a practical time period. In addition,
there are significant cost and logistic issues involved in
conducting traditional clinical trials in this uncommon
condition.
To overcome these obstacles, the Children’s Arthritis
and Rheumatology Research Alliance (CARRA) has
worked to develop consensus treatment plans (CTPs) to
study treatments in patients with rare rheumatic diseases
like JDM [13–15] and other pediatric inflammatory condi-
tions [16–18] to allow for pragmatic studies of treatments
and outcomes. These have been termed consensus clinical
treatment plans, as they have been developed by CARRA
members, through consensus methods. These CTPs are
meant to represent typical, commonly accepted treatment
approaches used by pediatric rheumatologists to treat
these illnesses. These commonly accepted treatment
approaches are generally based on anecdotal experi-
ence and have not been studied in the context of any
formal clinical trials.
The intent of the CTP is that each treating clinician
will be able to choose and follow a plan for the care of
their individual patient, which is similar to their typical
treatment approach. This will allow for increased
standardization of treatment approaches between insti-
tution review board (IRB) approved CARRA centers and
clinicians, and facilitate the prospective collection of
data through CARRA’s detailed registry, including: pa-
tient demographics, clinical and lab characteristics,
medication-related adverse events, as well as response to
treatments and outcomes. Using patient characteristics
and outcomes that will be collected prospectively, in-
novative statistical methods can be used to account for
the selection biases of non-random assignment to CTP
treatment groups, to estimate treatment effects compar-
able to those that might be obtained with traditional
randomized controlled trials [19–23].
Previously, a CTP for children presenting with moder-
ate JDM was published by CARRA [13, 14], and a pilot
study using that CTP was recently completed and
undergoing analysis. A second CTP was developed and
recently published for skin resistant JDM, characterized
by persistent skin rash despite resolution of muscle in-
volvement [15]. The goal of the present study is to de-
scribe the development of a third set of JDM CTPs for
skin predominant JDM, which applies to the distinct
subset of JDM patients, whose presentation is character-
ized by classic skin rash without significant muscle
involvement.
Methods
CARRA is a North American organization, made up
of pediatric rheumatologists and other medical profes-
sionals, interested in advancing research in pediatric
rheumatic conditions. It is comprised of more than
400 individuals from more than 110 centers, which
includes the majority of pediatric rheumatologists in
North America. CARRA’s mission is to “conduct col-
laborative research to prevent, treat and cure pediatric
rheumatic diseases”.
This CTP was developed over several years of collective
work and consensus building, with our CARRA
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collaborators, to represent typical care provided in
the pediatric rheumatology community. At each meet-
ing, results from previous surveys, consensus meet-
ings, as well as relevant literature were reviewed and
presented to participants. Surveys were sent to the
complete CARRA membership and members were
asked to complete the survey if they treated patients
with JDM and had sufficient expertise.
1. CARRA Annual Meeting, 2011—Miami, FL. During
this meeting, approximately 36 members of the
CARRA JDM Committee discussed the clinically
relevant JDM phenotypes for which additional
CTPs should be developed. It was agreed that
“skin disease” in JDM was important and
specifically patients presenting with rash but no
clinical weakness were considered to be a clinically
relevant subtype of JDM (so called “amyopathic and
hypomyopathic” JDM), which would include newly
diagnosed JDM patients. It was also agreed that
patients with “resistant skin disease” (i.e. patients with
typical JDM, who had persistent skin disease despite
resolution of muscle involvement following treatment)
were a distinct JDM subtype. It was agreed that these
subgroups should be considered separately [15].
There was general discussion regarding patient
characteristics of “amyopathic and hypomyopathic”
JDM and at this meeting, and it was decided that
the preferred descriptor for this subtype of JDM
patient would be “skin predominant JDM”. In
particular, since some cutaneous features of JDM are
considered pathognomonic, initiating treatment for
patients in this CTP with at least 6 weeks of skin
findings was agreed upon.
2. CARRA Annual Meeting, 2012—Las Vegas, NV. A
smaller core work group of 7 CARRA members
from the JDM Committee met to begin developing
components of the CTP, including the definition of
skin predominant JDM, inclusion and exclusion
criteria and a broad range of reasonable treatment
regimens, and four candidate treatment arms were
agreed upon. The initial candidate treatment
arms included 1) hydroxychloroquine alone, 2)
hydroxychloroquine and methotrexate, 3)
hydroxychloroquine, methotrexate and intravenous
immunoglobulin, and 4) hydroxychloroquine,
methotrexate, intravenous immunoglobulin and
corticosteroids.
3. Delphi Survey, Spring 2013— An electronic survey
was sent to all CARRA members (n = 400), to
present the consensus results from the 2012 meeting
for clarification regarding issues that had not been
satisfactorily addressed in the meetings. These issues
included whether skin predominant JDM was
broadly considered to be an important clinical issue,
and if members would consider using a CTP for the
treatment of this JDM subtype. Complete responses
were received from 97 CARRA members (73
pediatric rheumatologists, 7 internal medicine/
pediatric rheumatologists and 17 pediatric
rheumatology fellows). Of these, 31% had 0–4 years,
26% had 5–10 years and 43% had >10 years of
experience caring for patients with JDM. More than
82% of respondents considered themselves to be
moderately or very experienced in the care of JDM.
The majority of respondents agreed that skin
predominant JDM was an important clinical issue,
and would consider using a CTP to treat this JDM
subtype (92% and 98%, respectively). In addition,
91% of respondents agreed that rash for ≥ 6 weeks
was sufficient to include a patient in this CTP.
4. CARRA Annual Meeting, 2013—Chicago, IL.
Building on the results from the consensus meeting
from the previous year and the Delphi survey
results, a core group of 21 members of the CARRA
JDM Committee met. Nominal group methods [24]
were used to come to consensus, which was set at
≥75%. Issues addressed included clarification of
patient inclusion and exclusion criteria, minimum
evaluation for inclusion into these CTPs, interval of
monitoring and data collection, medications to be
included, the use of topical therapies, and the role of
additional diagnostic testing, including imaging and
biopsies. After additional review and discussion of
the candidate treatment arms, consensus was
reached to exclude the treatment option that
included IVIG, decreasing the number of treatment
arms to three. During the course of this meeting,
concern was expressed regarding the rarity of skin
predominant JDM, and it was suggested that
perhaps pediatric dermatologists were independently
seeing and managing this JDM subtype.
5. January 2014— Additional expertise was requested
and obtained from Pediatric Dermatology (PeDRA)
members in 2014. An electronic survey was sent out
to all PeDRA members (n = 146) to better
understand the degree to which they were managing
and treating skin predominant JDM. Forty PeDRA
members responded to the survey: 39 (98%) of the
respondents practiced in an academic setting. Most
had been in practice more than 5 years: 7 (18.0%)
for 6–9 years and 17 (43.6%) for >10 years. All
respondents agreed that better treatment and
understanding of this JDM subtype was important.
Thirty five (90%) reported that they refer all JDM
patients to a pediatric rheumatologist, and 30 (77%)
estimated that they see 1–5 amyopathic JDM
patients within the past 5 years.
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6. CARRA Annual Meeting, 2014—Orlando, FL. Twelve
members of the CARRA JDM Committee met to
further develop the CTPs and formally review the
PeDRA survey results. Nominal group methods [24]
were used to come to consensus, which was set at
≥75%. Further decisions regarding treatment arms,
medication dosing, use of topical therapies and
outcome assessment were made.
7. CARRA Annual Meeting, 2015—Austin, TX. Ten
members of the CARRA JDM Committee met to
finalize the proposed CTP. In addition, 2 PeDRA
members and one patient/parent representative from
CureJM participated in the meeting. The proposed
CTP was presented and using nominal group methods
[24] the complete CTP proposal was finalized.
A number of modifications were considered in this
meeting. Clarification regarding the age of JDM
patients and duration of symptoms needed were
made. Inclusion criteria were discussed in detail,
especially the definition of normal strength and
how it is determined by clinicians in light of the
challenges of strength testing in young children.
The three treatment arms were finalized, and all
participants agreed that topical therapies would be
explicitly monitored with this CTP. All respondents
agreed that presently available and validated tools
should be used to assess skin activity. Final
consensus was reached regarding recommendations
on steroid dose.
It was agreed that patients would be withdrawn
from this CTP if they developed weakness during
the course of treatment or required additional
systemic therapy. We reviewed and summarized our
work to date in order to develop CTPs which
reflected CARRA consensus on typical treatments
for JDM patients with skin predominant disease.
Results
The CTPs presented in this manuscript are intended for
patients with skin predominant JDM. CARRA members
reached consensus on the clinical characteristics of pa-
tients to be included in this subgroup of JDM (Table 1).
These patients are defined as children with cutaneous
manifestations of JDM skin disease for at least 6 weeks,
without any weakness detected by the patient/parent or
clinician. All patients included in this CTP require one
of the hallmark rashes of JDM, namely, Gottron’s pap-
ules or heliotrope rash, with or without other cutaneous
manifestations (e.g. Shawl sign, V-sign, malar rash, peri-
ungal erythema, vasculopathic changes in the nail bed
capillaries, etc.).
Patients may have mild calcinosis, determined by the
judgement of the treating clinician, but should not have
lipodystrophy or skin ulceration, since it was agreed that
patients with these findings have greater disease severity
beyond the context of this CTP. In addition, patients
should not have systemic involvement or findings of
other major organ involvement, including parenchymal
lung disease, dysphagia, aspiration, intestinal vasculitis,
or myocarditis, as assessed by the treating clinician.
Medication therapy in each of the CTPs is summarized
in Table 2. All treatment plans include hydroxychloro-
quine at 5mg/kg/day (maximum 400mg), with this as
monotherapy in Treatment option A. Treatment option B
includes the additional use of methotrexate, administered
by the parenteral route (preferred), at a dose of 15 mg/m2
or 1 mg/kg (maximum 40 mg) once weekly. Treatment
option C includes oral corticosteroids (prednisone at 1–2
mg/kg/day, maximum 60 mg) in conjunction with weekly
methotrexate, and daily oral hydroxychloroquine in the
same doses as treatment Plan B.
In all CTPs, appropriate sun avoidance and
maximization of sunscreen use, including broad spectrum
products with SPF ≥ 30, were recommended for all pa-
tients, with specific recommendations according to the
treating clinician. It was agreed that details regarding top-
ical therapies, which would include any topical steroids
and topical calcineurin inhibitors, including various for-
mulations and potencies, would be collected and recorded
in a detailed manner in the CARRA registry.
Since these CTPs deal with skin disease as the major
manifestation of JDM and resolution of skin features is
the primary outcome measure, there was extensive dis-
cussion about how skin disease would be assessed. Use
Table 1 Patient Characteristics for Skin Predominant Juvenile
Dermatomyositis (JDM)
Patients Inclusion Characteristics
1. Typical rash consistent with JDM for ≥6 weeks.
a. Should include Gottron’s papules or heliotrope rash
b. May have mild calcinosis and nailbed capillary abnormalities
2. No functional limitations or weakness
a. Based on history or CHAQ
b. As determined by treating physician based on strength
assessment
3. Muscle enzymes≤ 1.2 times upper limit of normal
a. Except if attributed to another process, such as exercise or
drug therapy
Patients Exclusion Characteristics
1. Significant systemic involvement, including parenchymal lung
disease, dysphagia, aspiration, intestinal vasculitis, myocarditis
2. Significant calcinosis, as determined by treating clinician
3. Ulcerative skin disease
4. Lipodystrophy
5. Pregnancy
Abbreviations: JDM juvenile dermatomyositis; CHAQ Childhood Health
Assessment Questionnaire
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of presently available assessment tools [25–29] was
weighed against the development of a novel assessment
tool more applicable to these specific CTPs. It was de-
cided that the cutaneous disease activity visual analogue
scale (VAS) from the Myositis Disease Activity Assess-
ment Tool (MDAAT) would serve as the primary out-
come [25, 30]. It was agreed that the development of a
novel tool was outside the scope of this current work.
This was a consensus decision supported by 91% of re-
spondents in the initial Delphi survey and 100% of par-
ticipants during the 2015 CARRA meeting.
Baseline investigations and data collection at follow-up
visits were common to all 3 CTPs (Table 3). It was
agreed that all patients would have basic investigations
at enrollment and at follow-up visits, suggested at a 3 to
4 month interval, to minimize the burden on busy clini-
cians. In addition, centers would have the option of col-
lecting additional data including autoantibody studies
and either the PRINTO or IMACS core set activity mea-
sures [25, 31, 32] at baseline and at follow-up.
It was agreed that treatment failure was defined as the
addition of any additional disease-modifying antirheu-
matic drugs to any of the three treatment options, or
any of the following: decline in the MDAAT, MD Global,
Extramuscular Disease Activity by ≥ 2 cm or worsening
of muscle enzymes by ≥20%. These patients would be
withdrawn from the CTP.
Discussion
We present a set of consensus clinical treatment plans
(CTPs) for children with JDM who have typical skin
rashes but no significant muscle weakness, which we call
skin predominant JDM.
Skin disease as a component of JDM is important
since it reflects disease activity and may contribute to
morbidity, including physical disfigurement, calcinosis
and lipodystophy. Skin disease is a manifestation of
Table 2 Consensus clinical treatment plans for Patients with
Skin Predominant Juvenile Dermatomyositis*
All patients should be asked to use optimal sun protection, including
regular use of broad spectrum sunscreen or sun block of SPF≥ 30
All other topical therapies (steroids, calcineurin inhibitors, etc.) should be
recorded
Treatment A
Hydroxychloroquine: 5mg/kg/day, maximum 400mg
Treatment B
Methotrexate subcutaneous, unless only oral administration is possible
−15 mg/m2 or 1 mg/kg (maximum 40 mg) once/week
Hydroxychloroquine: 5mg/kg/day, maximum 400mg
Treatment C
Prednisone
−1–2 mg/kg/day (maximum 60 mg)
Methotrexate subcutaneous, unless only oral administration is possible
−15 mg/m2 or 1 mg/kg (maximum 40 mg) once/week
Hydroxychloroquine: 5mg/kg/day, maximum 400mg
*Patients who develop weakness defined as need for additional disease-
modifying antirheumatic drugs, or any of the following: decline in the MDAAT,
MD Global, Extramuscular Disease Activity by ≥ 2cm or worsening of muscle
enzymes by ≥20%. would be withdrawn from this CTP but may then be eli-
gible to enter the CTPs for moderate JDM (13,14)
Table 3 Initial and Follow Up Assessments for Skin
Predominant Juvenile Dermatomyositis Patients
Initial
A. Basic Assessment
a. Cutaneous Disease Activity Visual Analogue Scale from the
Myositis Disease Activity Assessment Tool (MDAAT)
b. Physician global assessment of disease activity (10-cm VAS)
c. Patient/Parent global assessment of disease activity (10-cm VAS)
d. Physician Extramuscular disease activity (10-cm VAS)
e. CHAQ
f. Strength Testing: CMAS or Manual muscle testing
g. Documentation of muscle involvement if performed (e.g. MRI,
EMG, biopsy results)
h. Muscle enzymes (preferably several among serum levels of ALT,
AST, LDH, CK, aldolase)
i. Baseline laboratory testing (include complete blood cell count,
immunoglobulins)
j. Nailfold capillaroscopy (using hand-held magnifier, ophthalmo-
scope, or microscope)
B. Expanded assessment (Basic plus items below)
a. ANA and other autoantibodies (myositis-specific and myositis-
associated)
b. Full PRINTO core set activity measures, including Disease Activity
Score and Health-Related Quality of Life* [32]
Follow-up
A. Basic Assessment
a. Cutaneous Disease Activity Visual Analogue Scale from the
Myositis Disease Activity Assessment Tool (MDAAT)
b. Physician global assessment of disease activity (10-cm VAS)
c. Patient/Parent global assessment of disease activity (10-cm VAS)
d. Physician Extramuscular disease activity (10-cm VAS)
e. CHAQ
f. Strength Testing: CMAS or Manual muscle testing
g. Muscle enzymes (preferably several of ALT, AST, LDH, CK, aldolase)
h. Nailfold capillaroscopy (using hand-held magnifier, ophthalmo
scope, or microscope)
B. Expanded Assessment (Basic plus items below)
a. Full PRINTO core set activity measures [32]
* Note the basic assessment includes the International Myositis Assessment
and Clinical Studies (IMACS) Group core set measures for JDM [25]
Abbreviations: MDAAT Myositis Disease Activity Assessment Tool; VAS Visual
Analog Scale; CHAQ Childhood Health Assessment Questionnaire; CMAS
Childhood Myositis Assessment Scale; MRI magnetic resonance imaging; EMG
Electromyography; ALT alanine aminotransferase; AST aspartate
aminotransferase; LDH lactate dehydrogenase; CK creatine kinase; ANA
antinuclear antibody; PRINTO Pediatric Rheumatology International
Trials Organization
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active vasculopathy in JDM that is important to monitor
and treat [33, 34]. It has been reported that early severe
skin disease activity in JDM may predict cardiac dys-
function better than muscle disease [35], and persist-
ently active skin disease at 3 and 6 months after
diagnosis is predictive of continued active disease [36].
These data support the importance of adequate treat-
ment of JDM-related skin disease, since it may predict
worse outcomes [33–36]. There is limited knowledge of
patients with skin predominant JDM and optimal treat-
ment approaches, and studying this rare condition
using traditional clinical trials is not possible.
These CTPs are meant to represent typical, reasonable
treatment approaches taken by pediatric rheumatologists.
They are not standard of care, and do not replace clinical
judgment or decision making between the treating phys-
ician and patient. The intent of these CTPs are to provide
clinicians with reasonable medication options for treating
patients with skin predominant JDM, in hopes of dimin-
ishing differences in treatment approaches between clini-
cians across multiple CARRA centers. This in turn will
allow for improved prospective data collection of patient
responses to treatments through the CARRA registry.
Using statistical methods [22, 23], this prospective and
uniform data collection will allow us to compare dif-
ferences in patient outcomes in the three different
CTP options, which may estimate treatment effects
similar to those obtained with traditional randomized
controlled trials.
There are important limitations to consider with this
work. We chose to include patients with classic skin
findings of JDM for a minimum of 6 weeks. Though
most case definitions of this patient subtype suggest 6
months before formal classification [10], we note that in
clinical practice, treatment is usually initiated in a JDM
patient based on clinical indication, rather than an exact
duration of symptoms. Therefore we felt that inclusion
of these early patients for this CTP was reasonable and
reflected CARRA member practice patterns. In addition,
we are aware that nearly 25% of patients with skin pre-
dominant JDM progress to classic JDM with weakness,
over time. Thus, we included criteria for treatment failure,
and guidelines for withdrawal from this CTP, expecting
that some patients would evolve to classic JDM with
weakness over time. We hypothesize that early introduc-
tion of systemic treatment in skin predominant JDM may
delay or prevent the development of weakness, so formal
study of this is planned in the context of this work.
We involved a large number of pediatric rheumatolo-
gists in this consensus process, over the course of several
years. Responses to online surveys from CARRA and
PeDRA members were about 24 and 27%, respectively,
which can be considered a low response rate. We found
that survey responses pertaining to this topic are lower
compared to earlier surveys from CARRA [13, 14, 16,
17], however, it should be noted that our present sur-
vey response rates are comparable to current reported
online survey response rates [37, 38]. The surveys
were sent to the full CARRA and PeDRA member-
ship, and not a specific subset of JDM experts, but it
is reasonable to postulate that clinicians with more
exposure and expertise to JDM were more likely to
respond to the surveys. We postulate that survey re-
spondents were likely clinicians who have the most
interest and expertise in JDM, so it is possible that
these findings are not representative of all CARRA
and PeDRA members. In this regard, additional Del-
phi survey of the full participating group could have
been administered after finalizing the CTPs; however,
given the general response to the earlier Delphi sur-
veys, this was not performed. A previous CARRA sur-
vey, which collected information on medications used
by pediatric rheumatologists in North America to
treat skin predominant JDM, reported medications
combinations which overlap considerably with the
CTPs developed here [11]. Therefore, we are
confident our CTPS can be used broadly in clinical
practice and for larger scale, future study.
Topical therapies (sunscreens, steroids, calcineurin
inhibitors, etc.) are not explicitly included among the
separate treatment arms. The focus on systemic ther-
apy in this CTP, reflects consensus among the partici-
pating pediatric rheumatologists, who generally treat
these patients with systemic therapy, rather than top-
ical therapies alone. In addition, we recognized that
the power to detect a difference between the CTP op-
tions would be further diminished if various combina-
tions of topical therapies were included. However,
since we cannot discount the role of topical therapies,
which are used broadly in the treatment of skin pre-
dominant JDM, we plan to keep a strict record the
various topical therapies used. We will also account
for topical therapies in the final analysis, to assess if
patients treated with various topical therapies (e.g.,
topical corticosteroids and calcineurin inhibitors at
varying formulations and potencies) are associated
with a difference in outcome.
We note that we have not included all the treatment
options available, including early use of intravenous im-
munoglobulin therapy. Based on patient and clinician
preferences, these CTPs may not be applicable to all
patients with skin predominant JDM. These CTPs in-
clude systemic therapies, and are less immunosuppres-
sive compared to previously published CTPs developed
for patients with moderate weakness or ongoing rash,
which included more potent medications including,
high dose oral corticosteroids, pulse corticosteroids and
intravenous gammaglobulin [13–15].
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Conclusions
In conclusion, we present CTPs which are comple-
mentary to other treatment plans previously devel-
oped by the various disease-specific committees of
CARRA [13–18]. It is hoped that these CTPs can be
used prospectively to improve the understanding of
the best treatment approaches for this skin predomin-
ant subgroup of JDM patients and improve outcomes.
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